Provention Bio gives update on teplizumab BLA, FDA feedback

Provention Bio (NASDAQ:PRVB) said that the U.S. FDA has notified the company of "identified deficiencies" related to its ongoing review of the company's Biologic License Application (BLA) for teplizumab for the delay or prevention of clinical type 1 diabetes.